Predictors of Response to Therapy (Course BC01.05)
Published on November 27, 2007 Audio Interview
Published on November 27, 2007 Audio Interview
Click here to view our current activities in Oncology.
William J. Gradishar, MD, describes the latest clinical research illustrating the role of predictive markers in breast cancer therapy to achieve maximal response and progression-free survival. Dr. Gradishar also provides his expert recommendations on how to select among endocrine therapies, chemotherapies, and targeted treatments based on the results of endocrine receptor testing and HER2 testing. This audio interview represents Course 5 of Advanced Certificate Program: Breast Cancer Management
.
Harold J. Burstein, MD, PhD
- Associate Professor of Medicine
- Dana-Farber Cancer Institute
- Harvard Medical School
- Boston, Massachusetts
William J. Gradishar, MD, FACP
- Professor of Medicine
- Hematology/Oncology
- Northwestern University
- Chicago, Illinois
William J. Gradishar, MD, FACP, has received grant/research support from Abraxis BioScience, AstraZeneca PLC, GlaxoSmithKline, and Novartis Pharmaceuticals Corporation; and is a consultant for, is on the speakers bureau of, and is on the advisory board of Abraxis BioScience, AstraZeneca PLC, Genentech Inc, Genomic Health, Inc, GlaxoSmithKline and Novartis Pharmaceuticals Corporation.
Off-label use of lapatinib is included in this activity.
Lisa A. Carey, MD, ScM, has received grant/research support from Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, and GlaxoSmithKline; is a consultant for Pfizer Inc and Roche Pharmaceuticals; and is on the speakers bureau for Genentech, Inc and Pfizer Inc.
Marc L. Citron, MD, is on the speakers bureau for Abraxis BioScience, AstraZeneca PLC, Genentech, Inc, Genomic Health, Inc, GlaxoSmithKline, and Novartis Pharmaceuticals Corporation; and is a consultant for AstraZeneca PLC and Genentech, Inc.
Mehra Golshan, MD, has indicated no significant relationships.
William J. Gradishar, MD, FACP, has received grant/research support from Abraxis BioScience, AstraZeneca PLC, GlaxoSmithKline, and Novartis Pharmaceuticals Corporation; and is a consultant for, is on the Speakers Bureau of and is on the Advisory Board of Abraxis BioScience, AstraZeneca PLC, GlaxoSmithKline, Genentech Inc, Genomic Health, Inc and Novartis Pharmaceuticals Corporation.
Mark Pegram, MD, is a consultant to, is on the advisory boards of, and has received honoraria from Genentech, Inc, Glaxo SmithKline, Pfizer Inc, and Wyeth Pharmaceuticals.
Available for CME/CE:
Physicians
Publish Date: Nov 27, 2007 Termination Date: Nov 27, 2008Nurses
Publish Date: Nov 27, 2007 Termination Date: Nov 27, 2008Pharmacists
Publish Date: Nov 27, 2007 Termination Date: Nov 27, 2008Estimated time for completion of this activity:
CNE: 1.0 hour
CPE: 1.0 hour
Target Audience
This series of activities is designed for oncologists and other clinicians who specialize in and care for patients with breast cancer.
Activity Goal
The goal of these CME/CE activities is to examine current and emerging strategies for treating and managing patients with breast cancer.
Learning Objective (s)
- Describe the role and limitations of markers that predict response to therapy in breast cancer based on the most recent clinical trials.
- Select an appropriate endocrine therapy or chemotherapy regimen for treatment of breast cancer based on the results of endocrine receptor testing and HER2 testing to achieve maximal response and progression-free survival.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
This program has been approved by the American Association of Critical-Care Nurses (AACN) for 1.00 contact hour(s). Provider #00013784.
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This audio interview is worth up to 1.0 contact hour (0.1 CEU). The ACPE Universal Program Number assigned to this activity is 052-000-07-008-H01-P.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Harold J. Burstein, MD, PhD has indicated that he has no real or apparent conflicts of interest to report.
William J. Gradishar, MD, FACP has received grant/research support from Abraxis BioScience, AstraZeneca PLC, GlaxoSmithKline, and Novartis Pharmaceuticals Corporation; and is a consultant for, is on the speakers bureau of, and is on the advisory board of Abraxis BioScience, AstraZeneca PLC, Genentech Inc, Genomic Health, Inc, GlaxoSmithKline and Novartis Pharmaceuticals Corporation.
Off-label use of lapatinib is included in this activity.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Lauren A. Cerruto
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Harold J. Burstein, MD, PhD has indicated that he has no real or apparent conflicts of interest to report.
Lisa A. Carey, MD, ScM has received grant/research support from Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, and GlaxoSmithKline; is a consultant for Pfizer Inc and Roche Pharmaceuticals; and is on the speakers bureau for Genentech, Inc and Pfizer Inc.
Marc L. Citron, MD is on the speakers bureau for Abraxis BioScience, AstraZeneca PLC, Genentech, Inc, Genomic Health, Inc, GlaxoSmithKline, and Novartis Pharmaceuticals Corporation; and is a consultant for AstraZeneca PLC and Genentech, Inc.
Mehra Golshan, MD has indicated no significant relationships.
William J. Gradishar, MD, FACP has received grant/research support from Abraxis BioScience, AstraZeneca PLC, GlaxoSmithKline, and Novartis Pharmaceuticals Corporation; and is a consultant for, is on the Speakers Bureau of and is on the Advisory Board of Abraxis BioScience, AstraZeneca PLC, GlaxoSmithKline, Genentech Inc, Genomic Health, Inc and Novartis Pharmaceuticals Corporation.
Mark Pegram, MD is a consultant to, is on the advisory boards of, and has received honoraria from Genentech, Inc, Glaxo SmithKline, Pfizer Inc, and Wyeth Pharmaceuticals.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Genentech BioOncology
Novartis Pharmaceuticals Corporation
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: Nov 27, 2007 Termination Date: Nov 27, 2008Nurses
Publish Date: Nov 27, 2007 Termination Date: Nov 27, 2008Pharmacists
Publish Date: Nov 27, 2007 Termination Date: Nov 27, 2008Estimated time for completion of this activity:
CNE: 1.0 hour
CPE: 1.0 hour
Target Audience
This series of activities is designed for oncologists and other clinicians who specialize in and care for patients with breast cancer.
Activity Goal
The goal of these CME/CE activities is to examine current and emerging strategies for treating and managing patients with breast cancer.
Learning Objective (s)
- Describe the role and limitations of markers that predict response to therapy in breast cancer based on the most recent clinical trials.
- Select an appropriate endocrine therapy or chemotherapy regimen for treatment of breast cancer based on the results of endocrine receptor testing and HER2 testing to achieve maximal response and progression-free survival.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
This program has been approved by the American Association of Critical-Care Nurses (AACN) for 1.00 contact hour(s). Provider #00013784.
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This audio interview is worth up to 1.0 contact hour (0.1 CEU). The ACPE Universal Program Number assigned to this activity is 052-000-07-008-H01-P.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Harold J. Burstein, MD, PhD has indicated that he has no real or apparent conflicts of interest to report.
William J. Gradishar, MD, FACP has received grant/research support from Abraxis BioScience, AstraZeneca PLC, GlaxoSmithKline, and Novartis Pharmaceuticals Corporation; and is a consultant for, is on the speakers bureau of, and is on the advisory board of Abraxis BioScience, AstraZeneca PLC, Genentech Inc, Genomic Health, Inc, GlaxoSmithKline and Novartis Pharmaceuticals Corporation.
Off-label use of lapatinib is included in this activity.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Lauren A. Cerruto
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Harold J. Burstein, MD, PhD has indicated that he has no real or apparent conflicts of interest to report.
Lisa A. Carey, MD, ScM has received grant/research support from Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, and GlaxoSmithKline; is a consultant for Pfizer Inc and Roche Pharmaceuticals; and is on the speakers bureau for Genentech, Inc and Pfizer Inc.
Marc L. Citron, MD is on the speakers bureau for Abraxis BioScience, AstraZeneca PLC, Genentech, Inc, Genomic Health, Inc, GlaxoSmithKline, and Novartis Pharmaceuticals Corporation; and is a consultant for AstraZeneca PLC and Genentech, Inc.
Mehra Golshan, MD has indicated no significant relationships.
William J. Gradishar, MD, FACP has received grant/research support from Abraxis BioScience, AstraZeneca PLC, GlaxoSmithKline, and Novartis Pharmaceuticals Corporation; and is a consultant for, is on the Speakers Bureau of and is on the Advisory Board of Abraxis BioScience, AstraZeneca PLC, GlaxoSmithKline, Genentech Inc, Genomic Health, Inc and Novartis Pharmaceuticals Corporation.
Mark Pegram, MD is a consultant to, is on the advisory boards of, and has received honoraria from Genentech, Inc, Glaxo SmithKline, Pfizer Inc, and Wyeth Pharmaceuticals.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Genentech BioOncology
Novartis Pharmaceuticals Corporation
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|



